Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Sentís, Alexis;
Kislaya, Irina;
Nicolay, Nathalie;
Meijerink, Hinta;
Starrfelt, Jostein;
Martínez-Baz, Iván;
Castilla, Jesús;
Nielsen, Katrine Finderup;
Hansen, Christian Holm;
Emborg, Hanne-Dorthe;
+6 more...Nardone, Anthony;
Derrough, Tarik;
Valenciano, Marta;
Nunes, Baltazar;
Monge, Susana;
VEBIS-Lot4 working group;
(2022)
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Eurosurveillance, 27 (30).
ISSN 1560-7917
DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.